| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
|
| ln Vitro |
In RAW264.7 cells, LG100268 (100 nM-1 μM; 24 hours) caused a 2.5-fold reduction in CXCL2 and IL-1β mRNA expression, as well as downregulation of CSF3 [3].
|
|---|---|
| ln Vivo |
More than either C/P or LG268 alone, LG100268 (oral diet; 100 mg/kg; once daily; 7 weeks) and C/P together decreased mean tumor burden. In comparison to the control group, the combination significantly decreased lung tumors by 82% (as opposed to 59%–67% with the single drug) [3].
|
| Cell Assay |
Cell Viability Assay[3]
Cell Types: RAW264.7 Cell Tested Concentrations: 100 nM-1 μM Incubation Duration: 24 hrs (hours) Experimental Results: LPS-induced decrease in cytokine mRNA levels. |
| Animal Protocol |
Animal/Disease Models: A/J mice [3]
Doses: 50 mg/kg (in combination with carboplatin (50 mg/kg ip) starting 1 week after LG268 treatment diet) Route of Administration: Oral diet; one time/day; 7 weeks Experimental Results: Lung tumor growth in mice was Dramatically diminished. |
| References |
|
| Additional Infomation |
LG-100268 is a retinoid X receptor (RXR) selective compound.
|
| Molecular Formula |
C24H29NO2
|
|---|---|
| Molecular Weight |
363.5
|
| Exact Mass |
363.22
|
| CAS # |
153559-76-3
|
| PubChem CID |
3922
|
| Appearance |
White to off-white solid powder
|
| Density |
1.115g/cm3
|
| Boiling Point |
487ºC at 760mmHg
|
| Melting Point |
275-277ºC
|
| Flash Point |
248.3ºC
|
| Vapour Pressure |
0mmHg at 25°C
|
| Index of Refraction |
1.577
|
| LogP |
5.517
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
27
|
| Complexity |
591
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
SLXTWXQUEZSSTJ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C24H29NO2/c1-15-12-18-19(23(4,5)9-8-22(18,2)3)13-17(15)24(10-11-24)20-7-6-16(14-25-20)21(26)27/h6-7,12-14H,8-11H2,1-5H3,(H,26,27)
|
| Chemical Name |
6-[1-(3,5,5,8,8-pentamethyl-6,7-dihydronaphthalen-2-yl)cyclopropyl]pyridine-3-carboxylic acid
|
| Synonyms |
LG-100268.; LG 100268 ; LG100268
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~5.56 mg/mL (~15.30 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 0.56 mg/mL (1.54 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 5.6 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 0.56 mg/mL (1.54 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 5.6 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 0.56 mg/mL (1.54 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7510 mL | 13.7552 mL | 27.5103 mL | |
| 5 mM | 0.5502 mL | 2.7510 mL | 5.5021 mL | |
| 10 mM | 0.2751 mL | 1.3755 mL | 2.7510 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
